论文部分内容阅读
他汀类药物和依泽替米贝(ezetimibe)的临床结局试验中观察到低密度脂蛋白胆固醇(low-density lipoprotein cholesterol,LDL-C)水平降低(低至54mg/dL,1mmol/L=0.026mg/dL)与主要不良心血管事件(major adverse cardiovascular events,MACE)之间的连续关系。然而,LDL-C<50mg/dL人群中是否有存在上述联系尚不清楚。研究人员获取比较降胆固醇药alirocumab与对照组(安慰剂/依泽替米贝)的
Low-density lipoprotein cholesterol (LDL-C) levels were observed to be low (as low as 54 mg / dL, 1 mmol / L = 0.026 mg in clinical trials of statins and ezetimibe / dL) and major adverse cardiovascular events (MACE). However, it is unclear whether these associations exist among LDL-C <50 mg / dL populations. The researchers obtained a comparison of the cholesterol lowering drug alirocumab with the control group (placebo / ezetimibe)